Outpatient parenteral antimicrobial therapy today

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 2, 2010, Pages

  Paladino, Joseph A ^a,b   Poretz, Donald ^c  

^a CPL Associates   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Infectious Diseases Physicians   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN LACTOBIONATE; GANCICLOVIR; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; NAFCILLIN; PENICILLIN G; SULTAMICILLIN; UNINDEXED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; CENTRAL VENOUS CATHETER; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COAGULASE NEGATIVE STAPHYLOCOCCUS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECUBITUS; DIABETES MELLITUS; DIABETIC FOOT; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; EIKENELLA CORRODENS; ENTEROBACTERIACEAE; FEVER; FOREIGN BODY; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HOME INTRAVENOUS THERAPY; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MEDICAID; MEDICARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NURSE; OSTEOMYELITIS; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT CARE; OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY; PASTEURELLA MULTOCIDA; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; PHARMACY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REIMBURSEMENT; REVIEW; SALMONELLA; SICKLE CELL ANEMIA; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VASCULAR ACCESS; VIRUS INFECTION; VOMITING;

AMBULATORY CARE; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HOME CARE SERVICES, HOSPITAL-BASED; HUMANS; INFUSIONS, INTRAVENOUS; TREATMENT OUTCOME;

EID: 77957825273     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653520     Document Type: Review

References (48)

1. Kind AC, Williams DN, Gibson J. Outpatient intravenous antibiotic therapy: ten years' experience. Postgrad Med 1985; 77:105-108, 111.
2. Antoniskis A, Anderson BC, Van Volkinburg EJ, Jackson JM, Gilbert DN. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128:203-206. (Pubitemid 8337613)
3. Stiver HG, Telford GO, Mossey JM, et al. Intravenous antibiotic therapy at home. Ann Intern Med 1978; 89:690-693.
4. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248:336-339.
5. Poretz DM. Evolution of outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998; 12:827-834. (Pubitemid 29004649)
6. Williams DN, Rehm SJ, Tice AD, Bradley JS, Kind AC, Craig WA. Practice guidelines for community-based parenteral anti-infective therapy. IDSA Practice Guidelines Committee. Clin Infect Dis 1997; 25:787-801.
7. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J 2005; 98:590-595.
8. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278:32-39.
9. Tice A. The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes Registries. Chemotherapy 2001; 47(Suppl 1):5-16. (Pubitemid 33756306)
10. Tice AD. An overview of outpatient parenteral antimicrobial therapy. In: Tice AD, ed. Handbook of outpatient parenteral antimicrobial therapy. 2nd ed. Tarrytown, NY: CRG Publishing, 2005:9-21.
11. Petrak RM. Outpatient antibiotic therapy in long-term care facilities. Infect Dis Clin North Am 1998; 12:995-1008. (Pubitemid 29004660)
12. Howard L, Michalek AV. Home parenteral nutrition (HPN). Annu Rev Nutr 1984; 4:69-99.
13. Cox AM, Malani PN, Wiseman SW, Kauffman CA. Home intravenous antimicrobial infusion therapy: a viable option in older adults. J Am Geriatr Soc 2007; 55:645-650.
14. Moran GJ, Krishnadasan A, Gorwitz RJ, et al; EMERGency ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-674.
15. Liang BA. Case in health law. Cost containment and physician obligations: mandates for patient advocacy. Virtual Mentor 2006; 8:157-161.
16. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am 1998; 12:879-901. (Pubitemid 29004653)
17. Tice AD. Outpatient parenteral antimicrobial therapy for osteomyelitis. Infect Dis Clin North Am 1998; 12:903-919. (Pubitemid 29004654)
18. Kunkel MJ. Quality assurance and outcomes in outpatient parenteral antibiotic therapy. Infect Dis Clin North Am 1998; 12:1023-1034. (Pubitemid 29004662)
19. Nolet BR. Patient selection in outpatient parenteral antimicrobial therapy. Infect Dis Clin North Am 1998; 12:835-847. (Pubitemid 29004650)
20. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001; 161:61-65. (Pubitemid 32052144)
21. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic eval uation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91:462-470.
22. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
23. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157:47-56.
24. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia: results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997; 157:36-44.
25. H.R. 574: Medicare Home Infusion Therapy Coverage Act of 2009. The Library of Congress. Thomas. http://www.govtrack.us/congress/bill.xpd?bill=h111- 574. Accessed 30 November 2009.
26. S. 254: Medicare Home Infusion Therapy Coverage Act of 2009. The Library of Congress. Thomas. http://www.govtrack.us/congress/bill.xpd?bill=s111-254. Accessed 30 November 2009.
27. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: a novel antimicrobial. Int J Clin Pract 2007; 61:853-863.
28. Das B, Sarkar C, Biswas R, Pandey S. Review: Dalbavancin - a novel lipoglycopeptide antimicrobial for gram-positive pathogens. Pak J Pharm Sci 2008; 21:78-87.
29. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy: IDSA guidelines. Clin Infect Dis 2004; 38:1651-1672.
30. Williams DN, Raymond JL. Community-based parenteral anti-infective therapy (CoPAT): pharmacokinetic and monitoring issues. Clin Pharmacokinet 1998; 35:65-77.
31. Gorski LA. Integrating standards into practice - revised standards for home care infusion: what has changed? Home Healthc Nurse 2006; 24:627-631.
32. Mortlock N. Intravenous therapy in the acute care setting. In: Hankins J, Lonsway RA, Hendrick C, Perdue M, eds. Infusion therapy in clinical practice. 2nd ed. Philadelphia, PA: WB Saunders, 2001:469-500.
33. Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Drugs 2000; 59(Suppl 3):29-35.
34. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: Morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996; 17:552-557.
35. The American Hospital Association Hospital Statistics. Emerging trends in hospitals. Chicago, IL: American Hospital Association, 1998-1999.
36. Welch KE, Goff DA, Fish DN, et al. A multi-center economic analysis of bacteremia caused by methicillin-resistant Staphylococcus aureus. In: Proceedings of the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy (San Francisco). September 1999. Washington, D.C.: ASM Press; 2000.
37. Paladino JA, Sunderlin JL, Price CS, Schentag JJ. Economic consequences of antimicrobial resistance. Surg Infect (Larchmt) 2002; 3:259-267.
38. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med 1984; 77:77-83.
39. Eisenberg JM, Kitz DS. Savings from outpatient antibiotic therapy for osteomyelitis. Economic analysis of a therapeutic strategy. JAMA 1986; 255:1584-1588.
40. Chamberlain TM, Lehman ME, Groh MJ, Munroe WP, Reinders TP. Cost analysis of a home intravenous antibiotic program. Am J Hosp Pharm 1988; 45:2341-2345.
41. Kane RE, Jennison K, Wood C, Black PG, Herbst JJ. Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis patients. Pediatr Pulmonol 1988; 4:84-89.
42. Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics 2000; 18:451-457.
43. Dalovisio JP, Juneau J, Baumgarten, Kateiva J. Financial impact of a home intravenous antibiotic program on a Medicare managed care program. Clin Infect Dis 2000; 30:639-42.
44. Bernard L, El-hajj B, Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: Evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001; 26:445-451.
45. Carmeli Y, Mozaffari E. Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy 2002; 22:55S-62S.
46. Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002; 49:149-154.
47. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336:999-1007.
48. Berlin LH. Home care can cost more than hospitals. New York Times 26 June 1988; 4:26.